Wang Xian,Li Keyao,Yue Shuzhen,et al.Treatment selection and influencing factors of infantile hepatic hemangioma[J].Journal of Clinical Pediatric Surgery,,20():437-440,446.[doi:10.12260/lcxewkzz.2021.05.008]
Treatment selection and influencing factors of infantile hepatic hemangioma
- Keywords:
- Hemangioma/DT; Hemangioma/SU; Propranolol/AD; Propranolol/TU; Infant
- CLC:
- R732.2;R726
- Abstract:
- Objective To investigate the treatment choice and influencing factors of infantile hepatic hemangioma.Methods Retrospective analysis was made on the case data of 103 children with infantile hepatic hemangioma(IHH) treated in Hunan Children’s hospital from January 2013 to July 2020.According to the treatment methods,they were divided into three groups:oral propranolol group,surgical treatment group and outpatient observation group.The efficacy and safety of the three groups of cases were compared and analyzed,and univariate and multivariate analyses were performed by Logistic regression to explore the predictive influencing factors for the treatment of children with IHH.Results The total effective rates of the treatment group (66 cases) and the outpatient observation group (37 cases) were 84.84% and 59.46%,respectively; the recovery rates were 66.66% and 32.43%,respectively.The curative effect of patients in the treatment group was significantly higher than that of the outpatient observation group (χ2=12.4,P<0.05).The total effective rates of the oral propranolol group (49 cases) and the surgical treatment group (17 cases) were 79.59% and 100%,respectively,and the recovery rates were 61.22% and 82.35%,respectively.The surgical treatment group had higher efficacy than oral propranolol group (χ2=2.771,P<0.05).Multiple and diffuse hepatic hemangioma (OR=3.085,95%CI:1.250~7.609),combined with skin hemangioma (OR=18.163,95%CI:14.120~23.548),abnormal liver function (OR=0.345,95%CI:0.143~0.836),elevated vascular endothelial growth factor (OR=2.362,95%CI:1.089~3.265) is an independent influencing factor that requires treatment for infant hepatic hemangioma (P<0.05).Conclusion Oral propranolol therapy or surgical treatment of infantile hepatic hemangioma is safe and effective.Oral propranolol therapy is the first-line treatment for multiple or diffuse hepatic hemangioma.Multiple and diffuse hepatic hemangioma,combined with cutaneous hemangioma,abnormal liver function,and elevated vascular endothelial growth factor indicate that the patient needs treatment.
References:
1 Brown J,Arora R,Sethuraman U.Distributive Shock in a Neonate with Diffuse Infantile Hepatic Hemangioma[J].J Emerg Med,2018,54(1):e1-e3.DOI:10.1016/j.jeme-rmed.2017.09.016.
2 Joshi K,Bolia R,Poddar U,et al.Consumptive Hypothyroidism Due to Diffuse Hepatic Hemangiomas Treated With Propranolol Therapy[J].Indian Pediatr,2020,57(4):366-368.DOI:10.1007/s13312-020-1794-x.
3 Zavras N,Dimopoulou A,Machairas N,et al.Infantile hepatic hemangioma:current state of the art,controversies,and perspectives[J].Eur J Pediatr,2020,179(1):1-8.DOI:10.1007/s00431-019-03504-7.
4 Tsai MC,Liu HC,Yeung CY.Efficacy of infantile hepatic hemangioma with propranolol treatment:A case report[J].Medicine,2019,98(4):e14078.DOI:10.1097/MD.0000000000014078.
5 Zhang XT,Ren WD,Song G,et al.Infantile hepatic hemangiomas associated with high-output cardiac failure and pulmonary hypertension[J].BMC Cardiovasc Disord,2019,19(1):216.DOI:10.1186/s12872-019-1200-6.
6 IacobasI,Phung TL,Adams DM,et al.Guidance Document for HepaticHemangioma (Infantile and Congenital) Evaluation and Monitoring[J].J Pediatr,2018,203:294-300.e2.DOI:10.1016/j.jpeds.2018.08.012.
7 Emad A,Fadel S,El Wakeel M,et al.Outcome of Children Treated for Infantile Hepatic Hemangioendothelioma[J].J Pediatr Hematol Oncol,2020,42(2):126-130.DOI:10.1097/MPH.0000000000001536.
8 杨开颖,彭素华,邱桐,等.口服普萘洛尔治疗婴幼儿肝血管瘤的临床研究[J].临床小儿外科杂志,2020,19(2):145-149.DOI:10.3969/j.issn.1671-6353.2020.02.011. Yang KY,Peng SH,Qiu T,et al.Clinical study of oral propranolol in the treatment of infantile hepatic hemangioma[J].J Clin Ped Sur,2020,19 (2):145-149.DOI:10.3969/j.issn.1671-6353.2020.02.011.
9 杨开颖,彭素华,陈思源,等.婴幼儿肝血管瘤诊治现状[J].临床小儿外科杂志,2020,19(8):746-751.DOI:10.3969/j.issn.1671-6353.2020.08.016. Yang KY,Peng SH,Chen SY,et al.Diagnosis and treatment of infantile hepatic hemangioma[J].J Clin Ped Sur,2020,19 (8):746-751.DOI:10.3969/j.issn.1671-6353.2020.08.016.
10 Yang K,Peng S,Chen L,et al.Efficacy of propranolol treatment in infantile hepatic haemangioma[J].J Paediatr Child Health,2019,55(10):1194-1200.DOI:10.1111/jpc.14375.
11 Yang KY,Feng LW,Chen SY,et al.Progressive infantile hepatic hemangioma not responding to propranolol[J].J Dermatol,2019,46(8):e275-e276.DOI:10.1111/1346-8138.14833.
12 Ernst L,Grabhorn E,Brinkert F,et al.Infantile Hepatic Hemangioma:Avoiding Unnecessary Invasive Procedures[J].Pediatr Gastroenterol Hepatol Nutr,2020,23(1):72-78.DOI:10.5223/pghn.2020.23.1.72.
13 Cavalli R,Buffon RB,De Souza M,et al.Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma:rare complication or incidental finding?[J].Dermatology,2016,224(2):106-109.DOI:10.1159/000337553.
14 Ji Y,Chen S,Xu C,et al.The use of propranolol in thetreat nent of infantile haemangiomas:an updale on potential mechanisms of acion[J].Br J Dermatol,2015,172(1):24-32.DOI:10.111/bjd.13388.
15 Hsi Dickie B,Fishman SJ,Axzizkhan RG.Hepatic vascular tumors[J].Semin Pediar Surg,2014,23(4):168-172.DOI:10.103/j.sempedsurg.2014.06.018.
Memo
收稿日期:2020-11-24。
基金项目:湖南省卫生健康委科研课题（编号：20200341）
通讯作者:汤建萍,Email:jpingtang@126.com